Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fascinating ...just talking to a guy who writes algorithms for nanosecond trading predicting what other computers will do for trading - nanosecond day traders ....
THe implications here now fall solely onto AMRN's marketing
There is absolutely NO REASON for Lovaza scripts to have better performance then Vascepa - the only possible reason is lack of informed medical practitioners
THis is like having a 1 hp motor outperform a 10 HP motor - the only possible reason is the 10 HP is not being run appropriately !!!!
Someone NEEDS TO INFORM PRACTITIONERS about the difference and its not complicated !!!
They need to quit tweewting about daisies and unicorns and do something useful !!!
just get this into the hands of every doc !!!
**************************************
Appropriate classification and positioning of Omega 3 medications.
Lovaza (L) and Generic Lovaza (gL)
These are a combinations of EPA and DHA. The only appropriate utilization is for triglycerides > 500 to prevent pancreatitis. NONE of these drugs have any outcomes study showing any improvement in Cardiovascular outcomes! The only possible use of these medications is the reduction of triglycerides > 500 for the prevention of pancreatitis. Lovaza may actually induce cardiovascular disease since it increases LDL by 49%. These medications should NOT be listed as cardiovascular medicines.
Vascepa (V) and Generic Vascepa (gV)
These medications contain only EPA – both of these medication can be utilized for Trigs >500mg/dl, however, The vast majority of prescriptions written for Vascepa are for the REDUCE IT indications (individuals with known CAD or those with Diabetes and two risk factors on statins with trigs > 150 ), meaning it is being utilized to prevent cardiovascular disease. You cannot substitute Lovaza or generic lovaza for these prescriptions - they have NO indication for this and you may actually be harming the patient by increasing their LDL by 49% - Lovaza and Vascepa are DIFFERENT medications and are NOT Interchangeable.
Furthermore if a prescription is written for Vascepa for REDUCE IT indications (95% of use) you cannot substitute generic Vascepa – this is direct patent infringement and law suits are now being filed against insurers for such ( Healthnet). Generic Vascepa is ONLY approved for trigs >500 it is NOT approved for reduction of cardiovascular risk and doing so will expose you to liability for direct patent infringement.
In summary:
Omega 3's that can be used for Trigs >500
Lovaza – Generic Lovaza - Vascepa - Generic Vascepa
Omega 3's that can bu utilized for cardiovascular risk Reduction
VASCEPA
Probably are not anxious to release a PR saying they got their butts kicked ...
when the stock takes off YEE looks like he has no repsectable capability
ahh gotta love "The Fools"
can anyone on twitter help to inform this poor soul what happened
published 2:31 8 /5 no mention of TEVA case as reason for stock price increase ..
https://www.fool.com/investing/2021/08/05/why-amarin-is-soaring-today/
Docs get sued for malpractice ... and its not fun
To us its big news to the rest of the world ... they will get around to it eventually - if I was a short player Id short TEVA right now ...
AMrn should send a letter to HIKMA / Healthnet offering to settle for quadruple damages ...
and now for the herpes jokes ...
I named my dog herpes
because he never heels
Hear about the guy who got ocular herpes ?
He was looking for love in all the wrong places
I'll let myself out .....
Biotech powerball lottery ?
AMRN Rep dropped off advertising materials at my office and wrote 'make certain you DAW Rx's." They must be recognizing that generics are eating their lunch ...
They need to add a PBM - pharmacy benefits manager. From what I recall someone researched this and found that Healthnet is also a PBM ??
DOc writes rx ---> Pharmacist fills ----> pharmacist fills dependent on Insurance company approval (formulary) ---> Insurance company formulary managed by PBM. Manufacturers supply meds to pharmacy.
AMRN has gone after Insurer and Manufacturer - they need to add PBM and larger pharmacy chain - like Walgreens etc then all players are covered
Having said that I have all along said that I dotn think HIKMA is found guilty that my money rests on the insurer -
A motion to sever is a request by either the State or the defendant asking the court to have separate jury trials on the different charges. A motion to sever can also ask the court to sever the trials of co-defendants, resulting in the defendants being tried separately rather than together
If that were the case I dont think Thero would have stepped down ..
THe "french" spoke in kabek is equivalent to a 16th century dialect - they cant even understand one another ...lol
Thanks Capn !!
Manana.... an ethos of sloth and apathy
My biggest concern is that docs are well versed with sglt meds they view them as a "real" med and the mental link / reaction of
diabetes + heart disease needs prevention will automatically go to sglt's instead of vascepa -
The only way to prevent that is quick efficient effective marketing ... uggh ... I feel like we are sending the keystone cops up against a Navy Seal team ...
yes and its a direct competitor for Vascepa being marketed by people who know what they are doing ...
SO will BIden limit travel from CHina to the US ? But if he does that makes him a racist according to the media
Good message Patient just told me his copay for Vascepa dropped dramatically !!
Its multifactorial I have patients who have never smoked ldl is naturally under 100 low weight exercise no htn no diabetes and they have heart attacks -
Profit confirmed bought at $3.95
Dont recall if this was posted or not
https://www.medpagetoday.com/cardiology/prevention/93793
Bought at 3.95 now 4.26 - 8.6% gain in several days - should I sell KIWI ?
Dang I am not usually a short trader ....
Nice summary ... indirect rebuke of Nissen
I use medscape a lot and then American Family Physician and reps
I prefer meeting with a rep
Meeting with a rep insures that at least the message is heard
I literally block all pharmaceutical firms from communicating with me its just way too much repetitive redundant information snail mail goes immediately into the garbage
OK I have made 5% in a couple of days -- should probably sell what do you think KIWI ?
The way to frame this issue is as ff:
Say I came to pharmaceutical or investment firm and said
The #1 killer over age 40 in the modern world is CAD
There have been few pharmaceutical breakthroughs in 20 years
I have a medication with confirmed science that can reduce the #1 killer by 25 % -
they would be ecstatic to get their hands on it knowing it would be a blockbuster med
but that has not happened -
JASBG 25 years ago they use to do that they would have say a ski day and bring your family and listen to a lecture- but then our wonderful brilliant congress made it illegal - even getting pens - they can get $20,000 junkets but giving a doctor a 30 cent pen - no way -
I can just see it - 20 something snowflake with daisies and rainbows must be their head of marketing ....
Yes I bought too
Doubt if we can get this but...
I would like to see a weekly list of all advertising / marketing activities in the US
visits to practitioners presentations in the US all tweets all articles all posts in investor sites - all contacts of healthcare reporters - docs contacted to write supportive articles etc etc anything that their reps are doing to promote this product
let the people who have a vested interest in this company review what the workers are doing ....
WEll one of their marketing people has completed their weeks work ....
KM needs to clean house ASAP
It would be interesting to compare total Vascepa vs total Repatha
rx in the US - obviously Repatha being injectable and a lot more expensive should be substantially less - if its not then it would be difficult to conclude that price and methodology of delivery provide Vascepa an advantage vs the marketing capabilities of big pharma
but you have to sing the whole song KIWI and I didnt see any hip hip hooray
The information I posted was to reveal how other firms may potentially seek out the statin market - which will impact on AMRN's market - it is not to defend them it is not to say they are right or wrong it is simply to reveal that the market for prevention of CAD is going continue to be divided among various medications and this may clearly impact AMRN's market.
Sure you can cheer for me all you want
lets hear it KIWI !!!
Hip hip hooray
hip hip hooray
hip hip hooray
For hes a jolly good fellow for hes a jolly good fellow
for hes a jolly good fellow ... which nobody can deny !!
PCsk9s may Decrease progression to diabetes -
statins may increase progression to diabetes
Market that right and you make huge inroads to statin therapy
PCsk9's coming out with study showing limitation of progression to diabetes - they are going after statin market - and AMRN is tweeting about flowers and daisies and cant even operate a phone system ...hilarious ... KM really has his work cut out for him ...I am waiting to see what he does - in at $4.xx minimal lose here but on the other hand that money could be making more elsewhere